MONTREAL, Dec. 16, 2004 (PRIMEZONE) -- Viropro Pharma, a subsidiary of Viropro, Inc. (OTCBB:VPRO) is pleased to announce the addition of Dr. Max Bergoin, a world-renowned expert in microbiology, to its scientific advisory committee. Dr. Bergoin is a Full Professor and Head of the Microbiology Department at Universite de Montpellier II, France, as well as the Head of the Laboratory on Comparative Pathology.
Viropro Pharma's scientific advisory committee was recently created with the objective of pooling together the scientific and medical expertise of several internationally renowned experts. Dr. Bergoin thus joins a team with the mission of identifying and validating new innovative technologies and proven products as well as ensuring the successful transfer of technology to Viropro's clients and partners on an international scale. Over the next few months, the Company expects to announce several more appointments of this magnitude.
A graduate of L'Universite de Medecine de Marseille in France, Dr. Max Bergoin has, over many years, developed unique expertise as a scientific researcher for such prestigious institutions as the Centre National de Recherches Scientifiques (CNRS) - (National Scientific Research Center) of France. Throughout his career, Dr. Bergoin has also been an active member of several organizations and scientific committees as well as a prized speaker internationally. He has also authored several articles and books on Microbiology. In 1988, he was named Laureate of l'Academie Francaise des Sciences (The French Science Academy).
"We are both honoured and proud to have Dr. Max Bergoin join our scientific advisory committee", stated Dr. Patrick Barnabe, Viropro Pharma's new President. "His expertise as a researcher emeritus will contribute to effectively managing and extending a solid portfolio of innovative technologies and superior-quality biopharmaceutical products, providing Viropro Pharma with a positive, sustaining position in targeted foreign markets."
About Viropro
Viropro, Inc. (OTCBB:VPRO) is seeking to establish a growth portfolio in Life Sciences markets through strategic alliances and revenue-producing acquisitions with the potential for continued shareholder value.
Viropro, Inc's Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward looking statements". Forward looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.